Like The Knick's, Corcept Rebounded And Is Crushing It

Corcept Therapeutics is rated Strong Buy with $163 one-year and $222 two-year price targets, driven by explosive revenue and margin expansion. Lifyorli's rapid launch for platinum-resistant ovarian cancer and Korlym's resilient growth underpin 44%+ revenue growth and 98% gross margins, fueling EPS leverage. Based on my Lifyorli model, Street revenue and EPS estimates could be significantly low.

Seeking Alpha • Aug 21, 2026

Trump is up 230% on this stock trade since March

President Donald Trump disclosed a position in Corcept Therapeutics (NASDAQ: CORT) on March 4, when the pharmaceutical company was trading at $35.69.

Finbold • Aug 18, 2026

Raised Guidance Lifts Corcept to 52-Week High

CORT discovers, develops, and sells medications to treat severe metabolic, oncologic, and psychiatric disorders, focusing on the hormone cortisol (over 1,000 proprietary modulators) as well as Cushing's syndrome.

FXEmpire • Aug 5, 2026

Why Corcept Therapeutics (CORT) is a Top Momentum Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research • Aug 5, 2026

Corcept Therapeutics: LIFYORLI Is Likely A Blockbuster, But The Valuation Already Knows It

Corcept Therapeutics remains a 'Hold' as LIFYORLI's strong launch and clinical demand are already reflected in a premium valuation. LIFYORLI generated $47.6M in its first full quarter, with management targeting $1B+ US peak revenue and global NPV estimated at $4.24B. CORT's pipeline offers upside, notably with relacorilant in earlier PROC lines and EU approval pending, but non-LIFYORLI assets remain speculative.

Seeking Alpha • Jul 31, 2026

CORT Q2 Earnings & Revenues Beat Estimates, 2026 Outlook Raised

Corcept tops Q2 earnings estimates as Korlym growth and a strong Lifyorli launch lift revenues, prompting a higher 2026 top-line outlook.

Zacks Investment Research • Jul 30, 2026

Corcept Therapeutics Q2 Earnings Call Highlights

Corcept Therapeutics NASDAQ: CORT reported second-quarter 2026 revenue of $256.1 million, up 32% from the prior-year period, as sales from its Cushing's syndrome franchise increased and its newly launched ovarian cancer therapy LIFYORLI contributed $47.6 million in its first quarter of availability.

MarketBeat • Jul 29, 2026

Corcept Therapeutics Incorporated (CORT) Q2 2026 Earnings Call Transcript

Corcept Therapeutics Incorporated (CORT) Q2 2026 Earnings Call Transcript

Seeking Alpha • Jul 29, 2026

Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended June 30, 2026. Financial Results “Our oncology and Cushing's syndrome businesses delivered strong results in the second quarter. In our oncology busi.

Business Wire • Jul 29, 2026

Corcept Therapeutics (CORT) Q2 Earnings and Revenues Surpass Estimates

Corcept Therapeutics (CORT) came out with quarterly earnings of $0.36 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to earnings of $0.29 per share a year ago.

Zacks Investment Research • Jul 29, 2026